SCHEMBL607909

SCHEMBL607909

C/C=C/CC/C=C/C(N)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.39
PPARD Q03181 2/20 0.39
PPARA Q07869 2/20 0.39
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
FAAH O00519 3/20 0.34
SOAT1 P35610 2/20 0.34
POLB P06746 1/20 0.34
MEN1 O00255 1/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
F13A1 P00488 1/20 0.34
THRB P10828 1/20 0.34
PTGS1 P23219 1/20 0.34
FASN P49327 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CNR2 P34972 5/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL607910 1.00 PPARG (0.39) PPARGPPARDPPARAALDH1A1MAPT
SCHEMBL9805253 0.91 FAAH (0.45) PPARGPPARAALDH1A1MAPTFAAH
SCHEMBL9805247 0.91 FAAH (0.45) PPARGPPARAALDH1A1MAPTFAAH
SCHEMBL167052 0.87 ALDH1A1 (0.37) ALDH1A1MAPTFAAHSOAT1POLB
SCHEMBL2683878 0.84 CNR2 (0.49) PPARGPPARDPPARAALDH1A1MAPT
SCHEMBL2683876 0.84 CNR2 (0.49) PPARGPPARDPPARAALDH1A1MAPT
SCHEMBL4556984 0.84 CNR2 (0.49) PPARGPPARDPPARAALDH1A1MAPT
SCHEMBL31626917 0.82 CNR2 (0.51) PPARGPPARDPPARAALDH1A1MAPT
SCHEMBL8461708 0.79 PPARA (0.38) PPARAALDH1A1MAPTSOAT1CNR1
SCHEMBL2209835 0.78 PPARA (0.47) PPARGPPARDPPARAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353218-B2 Kit for multifunctional compounds forming crosslinked biomaterials ANGIOTECH PHARMACEUTICALS, INC. 2016-05-31 US disclosed
US-9326934-B2 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG 2016-05-03 US disclosed
EP-2181704-B1 Drug delivery from rapid gelling polymer composition ANGIOTECH INT AG (CH) 2015-05-06 EP disclosed
US-20130289235-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS, INC. (CA) 2013-10-31 US disclosed
US-8486437-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-07-16 US disclosed
US-8481073-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-07-09 US disclosed
US-8460708-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-06-11 US disclosed
US-20130012683-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-01-10 US disclosed
US-8303973-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2012-11-06 US disclosed
US-20120252905-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG 2012-10-04 US disclosed
WO-2005051452-A2 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051316-A2 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005046516-A2 MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-05-26 WO disclosed
US-20040260318-A1 Anastomotic connector devices ANGIOTECH INTERNATIONAL AG (CH) 2004-12-23 US disclosed
US-20040225077-A1 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG (CH) 2004-11-11 US disclosed
US-20040219214-A1 Tissue reactive compounds and compositions and uses thereof ANGIOTECH INTERNATIONAL AG (CH) 2004-11-04 US disclosed
WO-2004060346-A2 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG (CH) 2004-07-22 WO disclosed
WO-2004060405-A2 TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF ANGIOTECH INTERNATIONAL AG (CH) 2004-07-22 WO disclosed
US-4789687-A FOR REDUCTION OR PREVENTION OF BODY FAT ACCUMULATION AJINOMOTO CO., INC. (JP) 1988-12-06 US disclosed
US-4680313-A Acceleration of lipid metabolism using vanillylamine derivatives AJINOMOTO CO., INC. (JP) 1987-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040219214-A1 Tissue reactive compounds and compositions and uses thereof CD44, SELP, EPCAM PPARG 384/4885PPARD 521/4885PPARA 157/4885
US-20120252905-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION PGF, VCAM1, COL14A1 PPARG 3190/4885PPARD 3969/4885PPARA 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.